Deep vein thrombosis

Wandercraft, pioneer of walking robotics, opens U.S. corporate headquarters at Cure®, New York City's premier healthcare innovation campus

Retrieved on: 
星期二, 十二月 12, 2023
European Economic Area, Gait, Research, Engineering, Food, Organization, Tetraplegia, Spasm, Patient, Heart, FDA, Wheelchair, Movement, Health, Rehabilitation, Therapy, Neuroscience, Multiple sclerosis, Atalante, Pain, Walking, SCI, Deep vein thrombosis, Pharmaceutical industry, Medical device, Stroke, Cure

NEW YORK, Dec. 12, 2023 /PRNewswire/ -- Wandercraft, developer of the world's first in market self-stabilizing exoskeleton designed to enable people with walking impairments to stand and walk again, announced today the opening of its U.S. headquarters at Cure®, a healthcare innovation campus in New York City. The Company now has headquarters both in the U.S. where its CEO Matthieu Masselin has relocated, and in France where it originated, after receiving clearance from the U.S. Food and Drug Administration in early 2023 for its lead product, the hands-free Atalante X™ exoskeleton, for use in stroke rehabilitation.

Key Points: 
  • ET on Wednesday, Dec. 13 at Cure, 345 Park Avenue South, New York City.
  • The event will include demonstrations of its new Personal Exoskeleton that will offer new, revolutionary options to those of us in wheelchairs.
  • Wandercraft is joining Cure's group of start-up and established companies that have collectively raised more than $760 million since 2021.
  • The campus community offers residents opportunities to create synergies and collaborative partnerships with peer organizations that span medical technology, healthcare services, therapeutics, healthcare investment, academic research and non-profit initiatives.

Global Urokinase Market (2023-2028) by Type, Dose Strength, Indication, Applications, and Geography, Competitive Analysis, Impact of Covid-19 and Ansoff Analysis - ResearchAndMarkets.com

Retrieved on: 
星期四, 十一月 9, 2023
Health, Pharmaceutical, Stroke, Allergy, Headache, Incidence, Thrombosis, Vomiting, Laboratory, Prevalence, Face, Myocardial infarction, Pfizer, Clifton Springs Hospital & Clinic, Research, Bleeding, Nausea, Venous thrombosis, Pulmonary embolism, Abbott Laboratories, Fever, Chest pain, Deep vein thrombosis, DVT, Common, Geography, Marketing, Hospital, Atomic mass, Coagulopathy, Merck Group, Wilford Hall Ambulatory Surgical Center, Intracerebral hemorrhage, USD, Blood, Safety, Patient, Cardiovascular disease, COVID-19, Pharmaceutical industry, Birth control

The "Global Urokinase Market (2023-2028) by Type, Dose Strength, Indication, Applications, and Geography, Competitive Analysis, Impact of Covid-19 and Ansoff Analysis" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Urokinase Market (2023-2028) by Type, Dose Strength, Indication, Applications, and Geography, Competitive Analysis, Impact of Covid-19 and Ansoff Analysis" report has been added to ResearchAndMarkets.com's offering.
  • The urokinase market is being driven by the increasing prevalence of pulmonary embolism (PE), a condition characterized by blood clots in the lungs.
  • Urokinase, a thrombolytic agent, is used to dissolve these clots and is naturally produced by the human body.
  • The urokinase market is highly competitive, featuring numerous players involved in developing and marketing urokinase products.

A new anticoagulant in Pharmascience Canada's portfolio this fall!

Retrieved on: 
星期四, 十一月 2, 2023
Ischemia, Stroke, CAD, Peripheral artery disease, THR, Mortality, Atrial fibrillation, Coronary artery disease, Pulmonary embolism, Anticoagulant, PE, DVT, Rivaroxaban, Myocardial infarction, ASA, Deep vein thrombosis, TKR, Tablet, Safety, Patient, PAD, VTE, Phosphorus, Pharmaceutical industry

MONTREAL, Nov. 2, 2023 /CNW/ - Pharmascience Canada launches the generic drug Prpms-RIVAROXABAN, a product fully manufactured in Canada.

Key Points: 
  • MONTREAL, Nov. 2, 2023 /CNW/ - Pharmascience Canada launches the generic drug Prpms-RIVAROXABAN, a product fully manufactured in Canada.
  • It helps prevent blood clots from forming by directly blocking the activity of a clotting factor called Factor-Xa.
  • "Pharmascience is proud and committed to serving Canadian patients through the local production of our medications!
  • mentioned Mike Dutton, Vice President, and General Manager of Pharmascience Canada.

Late-Breaking Clinical Trial Results Announced at The VEINS 2023

Retrieved on: 
星期一, 十月 30, 2023
Trial of the century, RCT, Male, The, Thrombolysis, Dexamethasone, VIVID, PE, DVT, Hemodynamics, BPM, Deep vein thrombosis, PTS, VIVA, Safety, Patient, Ageing, Contraindication, Heart rate, CTA, Research, Quality of life, Syndrome, Anesthesia, Education, Villalta, USP, Freedom, Randomized controlled trial, Wynn Las Vegas, Birth control, Medical imaging, Pharmaceutical industry, Akura, Bullfrog

Below are highlights of this morning's 4 late-breaking clinical trial presentations.

Key Points: 
  • Below are highlights of this morning's 4 late-breaking clinical trial presentations.
  • These favorable clinical outcomes highlight the need for randomized controlled trial data comparing MT with standard of care anticoagulation treatment.
  • In the second phase of the trial, 60 participants will be enrolled 1:1 in a dual-blinded, randomized controlled trial (RCT).
  • Of the 21 patients followed at 1 month, 19 (90.5%) had fully compressible and two had partially compressible common femoral veins.

Press Release: Sanofi delivers first medicines from Global Health Unit’s Impact brand portfolio

Retrieved on: 
星期四, 十月 19, 2023
WHO, Coronary thrombosis, Capacity building, Vaccine, Notifiable disease, Conditional sentence, Diabetes, Malaria, Impact, GHU, Republic, Insulin glargine, Disease, Medicine, World Health Organization, Partnership, Deep vein thrombosis, Sanofi, Cancer, Tuberculosis, CNSS, Patient, Diagnosis, Cardiovascular disease, Pharmaceutical industry

Sanofi has delivered the first medicines from its Global Health Unit’s not-for-profit Impact brand portfolio to the Republic of Djibouti.

Key Points: 
  • Sanofi has delivered the first medicines from its Global Health Unit’s not-for-profit Impact brand portfolio to the Republic of Djibouti.
  • With this first shipment to Djibouti, Sanofi delivers on its commitment to improve and accelerate affordable and sustainable access to quality medicines, vaccines and healthcare for underserved populations.
  • To that point, the GHU created Impact, a unique not-for-profit brand with 30 standard-of-care medicines produced by Sanofi, some of which are considered "essential" by the World Health Organization (WHO).
  • “I'm delighted to see the very first Impact brand medicine, Enoxaparin Sodium Impact, arrive on Djibouti soil.

Aspen Medical Products Launches First Off-the-Shelf Cervical to Sacrum Spine System

Retrieved on: 
星期三, 十月 25, 2023
Patient, Length of stay, Spine, Trauma, LSO, Health, Aspen, William H. Harris (orthopaedic surgeon), American Academy of Orthopaedic Surgeons, American Academy, Risk, Pressure, TLSO, Research and development, Hospital, Deep vein thrombosis, Pain, Silviculture, Nursing, Pharmaceutical industry, Research

IRVINE, Calif., Oct. 25, 2023 /PRNewswire/ -- Aspen Medical Products (Aspen), the industry leader in spine solutions for pain and mobility management, has launched the VRTX System – the first fully integrated spinal support system on the market for post-operative and trauma care.

Key Points: 
  • IRVINE, Calif., Oct. 25, 2023 /PRNewswire/ -- Aspen Medical Products (Aspen), the industry leader in spine solutions for pain and mobility management, has launched the VRTX System – the first fully integrated spinal support system on the market for post-operative and trauma care.
  • Patients with traumatic, multi-level spinal injuries typically require a custom Cervical Thoracic Lumbar Sacral Orthosis (CTLSO) that stabilizes the spine before or after surgery.
  • The VRTX System is the first-ever cervical to sacrum system designed to redefine spinal care in acute care settings.
  • "Aspen is once again leading innovation and clinical solutions with the VRTX System," said Jim Cloar, Aspen's Chief Executive Officer.

FloBio Receives FDA's Breakthrough Device Designation for Bleeding Risk Diagnostic Test

Retrieved on: 
星期二, 十月 17, 2023
Diagnosis, Nursing care plan, Hospital, Food, Death, Stroke, DOAC, Mortality, Atrial fibrillation, Patient, FDA, Trauma, Anticoagulant, Regulation of tobacco by the U.S. Food and Drug Administration, Deep vein thrombosis, Emergency, Face, Physician, Birth control, Medical device

PHILADELPHIA, Oct. 17, 2023 /PRNewswire/ -- FloBio, a medical diagnostics company, announced today that the U.S. Food and Drug Administration has granted Breakthrough Device Designation for its rapid bleeding risk diagnostic test. The FDA recognizes that the device will provide for more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases or conditions. FloBio's test determines blood clotting status and whether a patient is on popular blood thinners called Direct Oral Anticoagulants (DOACs). This information would help emergency and critical care clinicians make informed treatment decisions about drug reversal to reduce serious bleeding, a major cause of preventable complications and death in US hospitals.

Key Points: 
  • PHILADELPHIA, Oct. 17, 2023 /PRNewswire/ -- FloBio , a medical diagnostics company, announced today that the U.S. Food and Drug Administration has granted Breakthrough Device Designation for its rapid bleeding risk diagnostic test.
  • The FDA recognizes that the device will provide for more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases or conditions.
  • FloBio's test determines blood clotting status and whether a patient is on popular blood thinners called Direct Oral Anticoagulants (DOACs).
  • This makes it difficult to  adequately prevent or manage bleeding in the face of trauma, invasive surgeries, stroke, and other medical conditions.

Inovia Vein Specialty Centers Commemorates World Thrombosis Day: Spreading Awareness on Deep Vein Thrombosis (DVT)

Retrieved on: 
星期三, 十月 11, 2023
General Health, Health, Surgery, Cardiology, Pain, Knowledge, Common, Tenderness, Prevalence, Vein, DVT, Travel, System, Swelling, Education, SE, Deep vein thrombosis, Pulmonary embolism, Red, Leg, Learning, Skin, Patient, Nursing, Birth control, Poultry farming, Tourism, Bend

As the world comes together to observe World Thrombosis Day on October 13th, 2023, Inovia Vein Specialty Centers proudly joins the global campaign to raise awareness about the prevalence and risks associated with Deep Vein Thrombosis (DVT).

Key Points: 
  • As the world comes together to observe World Thrombosis Day on October 13th, 2023, Inovia Vein Specialty Centers proudly joins the global campaign to raise awareness about the prevalence and risks associated with Deep Vein Thrombosis (DVT).
  • Inovia Vein Specialty Centers is dedicated to educating our communities about DVT, its signs, symptoms, and treatment options.
  • Deep Vein Thrombosis (DVT) occurs when blood clots form in the deep veins of the legs or other parts of the body.
  • About Inovia Vein Specialty Centers: Inovia Vein Specialty Centers is a leading provider of vein care services, committed to delivering top-quality care for patients with venous diseases.

World Thrombosis Day encourages public to "Move Against Thrombosis" to celebrate 10 years of raising awareness worldwide

Retrieved on: 
星期五, 十月 13, 2023
Foot, Coronary thrombosis, ISTH, Thrombosis, Death, International Society, Tenderness, Chest pain, Pelvis, Uterus, Organization, VTE, DVT, Hospital, Travel, Pregnancy, Calf, Heart rate, Cancer, Movement, Blood, Thrombus, Pulmonary embolism, International Society on Thrombosis and Haemostasis, Patient, Walking, Leg, Deep vein thrombosis, Vein, Ankle, Risk, Birth control

World Thrombosis Day engages 5,000 partner organizations from 120 countries to advance understanding of the treatment and prevention of blood clots.

Key Points: 
  • World Thrombosis Day engages 5,000 partner organizations from 120 countries to advance understanding of the treatment and prevention of blood clots.
  • For its 10th anniversary year, the campaign encourages people to Move Against Thrombosis with simple movements to increase blood flow.
  • Thrombosis can develop in, or travel to, blood vessels throughout the body, often causing symptoms that can be mistaken for other conditions.
  • Incorporating movement in blood clot prevention inspired World Thrombosis Day's Move Against Thrombosis theme.

World Thrombosis Day encourages public to "Move Against Thrombosis" to celebrate 10 years of raising awareness worldwide

Retrieved on: 
星期五, 十月 13, 2023
Foot, Coronary thrombosis, ISTH, Thrombosis, Death, International Society, Tenderness, Chest pain, Pelvis, Uterus, Organization, VTE, DVT, Hospital, Travel, Pregnancy, Calf, Heart rate, Cancer, Movement, Blood, Thrombus, Pulmonary embolism, International Society on Thrombosis and Haemostasis, Patient, Leg, Deep vein thrombosis, Vein, Ankle, Risk, Birth control

World Thrombosis Day engages 5,000 partner organizations from 120 countries to advance understanding of the treatment and prevention of blood clots.

Key Points: 
  • World Thrombosis Day engages 5,000 partner organizations from 120 countries to advance understanding of the treatment and prevention of blood clots.
  • For its 10th anniversary year, the campaign encourages people to Move Against Thrombosis with simple movements to increase blood flow.
  • Thrombosis can develop in, or travel to, blood vessels throughout the body, often causing symptoms that can be mistaken for other conditions.
  • Incorporating movement in blood clot prevention inspired World Thrombosis Day's Move Against Thrombosis theme.